These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 32031055)
1. Genomic and Transcriptomic Characterization of Sporadic Medullary Thyroid Carcinoma. Qu N; Shi X; Zhao JJ; Guan H; Zhang TT; Wen SS; Liao T; Hu JQ; Liu WY; Wang YL; Huang S; Shi RL; Wang Y; Ji QH Thyroid; 2020 Jul; 30(7):1025-1036. PubMed ID: 32031055 [No Abstract] [Full Text] [Related]
2. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma. Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802 [TBL] [Abstract][Full Text] [Related]
3. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma. Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163 [TBL] [Abstract][Full Text] [Related]
4. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations. Barletta JA; Nosé V; Sadow PM Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588 [TBL] [Abstract][Full Text] [Related]
5. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways. Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Mian C; Pennelli G; Fassan M; Balistreri M; Barollo S; Cavedon E; Galuppini F; Pizzi M; Vianello F; Pelizzo MR; Girelli ME; Rugge M; Opocher G Thyroid; 2012 Sep; 22(9):890-6. PubMed ID: 22747440 [TBL] [Abstract][Full Text] [Related]
7. Polymorphisms Within the Gemignani F; Romei C; Ciampi R; Corrado A; Melaiu O; Figlioli G; Bonotti A; Foddis R; Cristaudo A; Pellegrini G; Vivaldi A; Cipollini M; Landi S; Elisei R Thyroid; 2020 Nov; 30(11):1579-1588. PubMed ID: 32228166 [No Abstract] [Full Text] [Related]
8. RET oncogene mutations in medullary thyroid carcinoma in Mexican families. González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374 [TBL] [Abstract][Full Text] [Related]
9. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma. Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696 [TBL] [Abstract][Full Text] [Related]
10. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Figlioli G; Landi S; Romei C; Elisei R; Gemignani F Mutat Res; 2013; 752(1):36-44. PubMed ID: 23059849 [TBL] [Abstract][Full Text] [Related]
11. Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on ret proto-oncogene activity. Zhu W; Hai T; Ye L; Cote GJ J Clin Endocrinol Metab; 2010 Jan; 95(1):439-44. PubMed ID: 19897677 [TBL] [Abstract][Full Text] [Related]
12. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report. Menon MM; Simha MR Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654 [TBL] [Abstract][Full Text] [Related]
13. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907 [TBL] [Abstract][Full Text] [Related]
14. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926 [TBL] [Abstract][Full Text] [Related]